ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In CML, increased levels of MDSC, which originate from the malignant BCR-ABL1 clone, are also observed, and these MDSC subsequently reduce following highly efficacious TKI therapy (12, 13).